Scrambler Therapy to Reduce Neuropathic Pain in Adults with Corticobasal Syndrome

What this Trial Is About

Researchers are evaluating whether scrambler therapy ST can effectively reduce neuropathic pain in patients with corticobasal syndrome CBS, a rare and progressive parkinsonian disorder that causes severe pain impacting quality of life. This pilot trial aims to determine if ST can lower pain scores by at least 33% within one month, which would support further larger studies. CBS currently has no disease-modifying treatments, making pain management an urgent need. Participants will be randomly assigned to receive either scrambler therapy or transcutaneous electrical nerve stimulation TENS initially, with all eventually receiving scrambler therapy. Both treatments use superficial electrocardiogram ECG electrodes placed on the areas of pain, delivering electrical stimulation for 30 to 40 minutes or until pain relief occurs. Scrambler therapy sends non-pain signals to modify nerve pathways, while TENS uses low-voltage current for pain relief. During the study, participants will have their pain levels monitored using patient-reported measures such as the Modified Brief Pain Index and the Patient Global Impression of Change over 30 and 90 days. Researchers will assess changes in daily pain and overall improvement. The trial includes safety monitoring and informed consent, with participation lasting at least three months and follow-up assessments to evaluate treatment effects and pain relief.

Scrambler Therapy for Corticobasal Syndrome-Associated Pain